Precipio, Inc. announced on February 25, 2025, that it achieved two important financial goals in the fourth quarter of 2024. The company reported positive Adjusted EBITDA of $0.4 million for Q4 2024.
Additionally, Precipio recorded a positive cash flow, with an increase of $0.3 million in cash during Q4 2024. Of this improvement, $75,000 was attributed to directors’ fees paid in stock, with the balance representing cash flow from operations.
Management stated that these results demonstrate the company’s ability to achieve and sustain financial independence by generating sufficient positive cash flow from its pathology service division. This cash flow is intended to fund ongoing research and development, as well as continued investment in the high-value product business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.